PaulMCopelandMD

Endocrinology • Lynn, MA

Adrenal Disease, Diabetes, Obesity, Thyroid

Director of Outreach, Massachusetts General Hospital Weight Center

Join to view full profile

Dr. Copeland is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Copeland's full profile

Already have an account?

Office
480 Lynnfield St
Lynn, MA 01904
Phone+1 781-593-3400

Fax+1 781-477-1193
Is this information wrong?

Summary

Dr. Paul Copeland is an endocrinologist in Lynn, MA and is affiliated with the Massachusetts General Hospital Weight Center. He received his medical degree from Yale School of Medicine and has been in practice 39 years. He specializes in adrenal disease, diabetes, obesity, and thyroid and is experienced in general endocrinology and osteoporosis. He has more than 50 publications and over 500 citings.

Education & Training

Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1981 - 1984
University of Pennsylvania Health SystemResidency, Internal Medicine, 1978 - 1981
Yale School of MedicineClass of 1978

Certifications & Licensure

MA State Medical License 1982 - 2025
PA State Medical License 1979 - 1982
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
American Board of Obesity Medicine Obesity Medicine
International Society for Clinical DensitometryClinical Densitometrist

Awards, Honors, & Recognition

Dr. Bennett I. Solomon Community Leadership Award Cohen Hillel Academy, 2014
Outstanding Clinical Practitioner Laureate Award The Endocrine Society, 2014
Regional Top Doctor Castle Connolly, 2014

Publications & Presentations

PubMed

2 citations
EDITORIAL: Eating disorders in diabetes: Discussion on issues relevant to type 1 diabetes and an overview of the Journal's special issue.
Ann Goebel-Fabbri, Paul M. Copeland, Stephen Touyz, Phillipa Hay> ;Journal of Eating Disorders. 2019 Jul 18
3 citations
Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial
Xiaoduo Fan, Paul M. Copeland, Shukair Nawras, Amy Harrington, Oliver Freudenreich, Donald C. Goff, David C. Henderson> ;Psychopharmacology. 2019 Feb 12
13 citations
Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder.
Katlyn L. Nemani, M. Claire Greene, Melissa Ulloa, Brenda Vincenzi, Paul M. Copeland, Sulaiman Al-Khadari, David C. Henderson> ;Clinical Schizophrenia & Related Psychoses. 2017 Nov 22
4 citations
Salsalate as an adjunctive treatment for psychopathology and cognition in patients with schizophrenia: a pilot study.
Yanli Luo, Fang Liu, Radhika Natarajan, Nawras Shukair, Paul M. Copeland, Xiaoduo Fan> ;International Clinical Psychopharmacology. 2017 Oct 1
179 citations
Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses
David C. Henderson, Brenda Vincenzi, Nicolas V Andrea, Melissa Ulloa, Paul M. Copeland> ;The Lancet. Psychiatry. 2015 May 1
46 citations
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and l...
Brenda Vincenzi, Shannon Stock, Christina P.C. Borba, Sarah M. Cleary, Claire E. Oppenheim, Liana J. Petruzzi, Xiaoduo Fan, Paul M. Copeland, Oliver Freudenreich, Cori...> ;Schizophrenia Research. 2014 Nov 1
14 citations
No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia
Jie Li, Xue Li, Emily Y. Liu, Paul M. Copeland, Oliver Freudenreich, Donald C. Goff, David C. Henderson, Xueqin Song, Xiaoduo Fan> ;Schizophrenia Research. 2013 May 1
12 citations
An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics.
Brenda Vincenzi, Christina P.C. Borba, Deborah A. Gray, Paul M. Copeland, Xingyue Wang, Xiaoduo Fan, Gowri G Aragam, David C. Henderson> ;Annals of Clinical Psychiatry. 2013 May 1
14 citations
No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia.
Xiaoduo Fan, Emily Y. Liu, Oliver Freudenreich, Paul M. Copeland, Douglas Hayden, Musie Ghebremichael, Bruce M. Cohen, Dost Öngür, Donald C. Goff, David C. Henderson> ;Journal of Clinical Psychopharmacology. 2013 Apr 1
41 citations
Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia.
Xiaoduo Fan, Christina P.C. Borba, Paul M. Copeland, Doug Hayden, Oliver Freudenreich, Donald C. Goff, David C. Henderson> ;Acta Psychiatrica Scandinavica. 2013 Mar 1
28 citations
Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia.
Christina P.C. Borba, Xiaoduo Fan, Paul M. Copeland, Alexander Paiva, Oliver Freudenreich, David C. Henderson> ;Journal of Clinical Psychopharmacology. 2011 Oct 1
14 citations
Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia.
David C. Henderson, Oliver Freudenreich, Christina P.C. Borba, Xingyue Wang, Paul M. Copeland, Eric A. Macklin, Xiaoduo Fan, Corinne Cather, Donald C. Goff> ;Schizophrenia Research. 2011 Aug 1
16 citations
No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophrenia.
Xiaoduo Fan, Paul M. Copeland, Emily Y. Liu, Elaine Chiang, Oliver Freudenreich, Donald C. Goff, David C. Henderson> ;Journal of Clinical Psychopharmacology. 2011 Apr 1
16 citations
Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone.
David C. Henderson, Bikash Sharma, Xiaoduo Fan, Paul M. Copeland, Christina P.C. Borba, Oliver Freudenreich, Corinne Cather, A. E. Evins, Donald C. Goff> ;Annals of Clinical Psychiatry. 2010 Feb 1
5 citations
An Algorithm for the Care of Type 2 Diabetes
Alan Cole, David M. Nathan, Elizabeth Savaria-Porter, Paul M. Copeland, Alexander Turchin, Melanie Brunt, Randall M. Zusman, Jo-Ann Barrett, Deborah J. Wexler, Emily C...> ;Critical Pathways in Cardiology. 2009 Dec 1
16 citations
Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.
David C. Henderson, Xiaoduo Fan, Bikash Sharma, Paul M. Copeland, Christina P.C. Borba, Oliver Freudenreich, Corinne Cather, A. Eden Evins, Donald C. Goff> ;Journal of Psychiatric Practice. 2009 Jul 1
34 citations
A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.
David C. Henderson, Xiaoduo Fan, Bikash Sharma, Paul M. Copeland, Christina P.C. Borba, Ryan Boxill, Oliver Freudenreich, Corey Cather, A. Eden Evins, Donald C. Goff> ;Acta Psychiatrica Scandinavica. 2009 Jun 1
21 citations
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia
David C. Henderson, Xiaoduo Fan, Paul M. Copeland, Bikash Sharma, Christina P.C. Borba, Sharon Forstbauer, Kate Miley, Ryan Boxill, Oliver Freudenreich, Corrine Cather...> ;Human Psychopharmacology. 2009 Apr 1
59 citations
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.
David C. Henderson, Xiaoduo Fan, Paul M. Copeland, Bikash Sharma, Christina P.C. Borba, Ryan Boxill, Oliver Freudenreich, Corinne Cather, A. Eden Evins, Donald C. Goff> ;Journal of Clinical Psychopharmacology. 2009 Apr 1
Adrenal masses.
Miller, J.C., Blake, M.A., Boland, G.W., Copeland, P.M., Thrall, J.H., Lee, S.I.> ;J Am Coll Radiol. 2009 Mar
59 citations
Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics.
David C. Henderson, Enrico Cagliero, Paul M. Copeland, Pearl M. Louie, Christina P.C. Borba, Xiaoduo Fan, Oliver Freudenreich, Donald C. Goff> ;The Journal of Clinical Psychiatry. 2007 Apr 16
49 citations
A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain
David C. Henderson, Xiaoduo Fan, Paul M. Copeland, Christina P.C. Borba, Tara B. Daley, Dana D. Nguyen, Haiyue Zhang, Doug Hayden, Oliver Freudenreich, Corinne Cather,...> ;Acta Psychiatrica Scandinavica. 2007 Feb 1
10 citations
Higher Fasting Serum Insulin Is Associated with Increased Resting Energy Expenditure in Nondiabetic Schizophrenia Patients
Xiaoduo Fan, Ellen J. Anderson, Paul M. Copeland, Christina P.C. Borba, Dana D. Nguyen, Oliver Freudenreich, Donald C. Goff, David C. Henderson> ;Biological Psychiatry. 2006 Dec 15
How successful are commercial weight-loss programs?
Paul M. Copeland> ;Nature Clinical Practice. Endocrinology & Metabolism. 2006 Dec 1
48 citations
Adrenocortical carcinoma: contrast washout characteristics on CT.
James Slattery, Michael A. Blake, Mannudeep K. Kalra, Joseph Misdraji, Ann T. Sweeney, Paul M. Copeland, Peter R. Mueller, Giles W. Boland> ;AJR. American Journal of Roentgenology. 2006 Jul 1
Join now to see all